-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GoqUfQ+hklFwyfcbGMqWA7oIDV35VxpTux2V9q0yezbfPuN70IqCRk62ZW4nIAQ7 l3ejGPQ334+mj7nCL8aIsg== 0000950148-99-000968.txt : 19990430 0000950148-99-000968.hdr.sgml : 19990430 ACCESSION NUMBER: 0000950148-99-000968 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19990331 FILED AS OF DATE: 19990429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DIAGNOSTIC PRODUCTS CORP CENTRAL INDEX KEY: 0000702259 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 952802182 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: SEC FILE NUMBER: 001-09957 FILM NUMBER: 99604185 BUSINESS ADDRESS: STREET 1: 5700 W 96TH ST CITY: LOS ANGELES STATE: CA ZIP: 90045 BUSINESS PHONE: 2137760180 10-Q 1 FORM 10-Q 1 ================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 1999 [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission file number 1-9957 Diagnostic Products Corporation (Exact name of registrant as specified in its charter) CALIFORNIA 95-2802182 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 5700 WEST 96TH STREET LOS ANGELES, CALIFORNIA 90045 (Address of principal executive offices) Registrant's telephone number: (310) 645-8200 NO CHANGE (Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [YES X] [NO ] The number of shares of Common Stock, no par value, outstanding as of March 31, 1999, was 13,676,129. ================================================================================ 2 PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS. DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (unaudited)
(In thousands, except per share data) Three Months Ended March 31, ------------------------- 1999 1998 -------- -------- SALES $ 50,466 $ 46,104 -------- -------- COSTS AND EXPENSES: Cost of sales 23,206 20,395 Selling 9,562 9,012 Research and development 5,806 5,409 General and administrative 6,754 5,926 Equity in income of affiliates (480) (344) Interest income-net (272) (118) -------- -------- Total costs and expenses 44,576 40,280 -------- -------- INCOME BEFORE INCOME TAXES 5,890 5,824 PROVISION FOR INCOME TAXES 1,790 1,720 -------- -------- NET INCOME $ 4,100 $ 4,104 ======== ======== EARNINGS PER SHARE: Basic $ .30 $ .30 Diluted .30 .30 AVERAGE SHARES OUTSTANDING: BASIC 13,669 13,746 DILUTIVE EFFECT OF STOCK OPTIONS 149 161 -------- -------- DILUTED 13,818 13,907 ======== ========
1 3 DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (unaudited)
(Dollars in Thousands) March 31, December 31, 1999 1998 --------- ----------- ASSETS CURRENT ASSETS: Cash and cash equivalents $14,480 $18,650 Accounts receivable-net of allowance for doubtful accounts of $130 and $136 53,852 50,440 Inventories 54,318 54,078 Prepaid expenses and other current assets 284 580 Deferred income taxes 3,305 3,305 -------- -------- Total current assets 126,239 127,053 PROPERTY, PLANT AND EQUIPMENT: Land and buildings 36,003 35,878 Machinery and equipment 61,012 60,196 Leasehold improvements 7,135 7,135 Construction in progress 579 351 -------- -------- Total 104,729 103,560 Less accumulated depreciation and amortization 50,946 49,348 -------- -------- Property, plant and equipment - net 53,783 54,212 SALES-TYPE AND OPERATING LEASES 30,623 33,372 DEFERRED INCOME TAXES 2,005 2,005 INVESTMENTS IN AFFILIATED COMPANIES 14,186 15,509 EXCESS OF COST OVER NET ASSETS ACQUIRED- Net of amortization of $8,748 and $8,478 14,584 14,073 -------- -------- TOTAL ASSETS $241,420 $246,224 ======== ======== LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Notes payable $18,408 $21,178 Accounts payable 15,435 15,306 Accrued liabilities 6,271 6,218 Income taxes payable 4,804 3,350 -------- -------- Total current liabilities 44,918 46,052 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Common Stock-no par value, authorized 30,000,000 shares; outstanding 13,676,129 shares and 13,661,594 shares. 37,826 37,531 Retained earnings 175,360 172,900 Accumulated other comprehensive income (16,684) (10,259) -------- -------- Total shareholders' equity 196,502 200,172 -------- -------- TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $241,420 $246,224 ======== ========
2 4 DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
(Dollars in Thousands) Three Months Ended March 31, ----------------------- 1999 1998 -------- -------- Cash Flows from Operating Activities: Net income $ 4,100 $ 4,104 Adjustments to reconcile net income to net cash flows from operating activities: Depreciation and amortization 4,799 3,762 Equity in undistributed income of unconsolidated affiliates (420) (79) Accounts receivable (5,603) (2,673) Inventories (576) (740) Prepaid expenses and other current assets 296 148 Accounts payable 2,745 (1,505) Accrued liabilities 53 188 Income taxes payable 1,283 1,490 -------- -------- Net cash flows from operating activities 6,677 4,695 Cash Flows from (used for) Investing Activities: Additions to property, plant and equipment (2,852) (2,597) Sales-type and operating leases (4,458) (2,077) Investment in affiliated companies (307) (2,612) -------- -------- Net cash from (used for) investing activities (7,617) (7,286) Cash Flows from (used for) Financing Activities: Borrowing - net (1,206) 544 Proceeds from exercise of stock options 295 1,156 Cash dividends paid (1,640) (1,649) -------- -------- Net cash from (used for) financing activities (2,551) 51 Effect of exchange rate changes on cash (679) (243) -------- -------- Net Increase (Decrease) in Cash and Cash Equivalents (4,170) (2,783) Cash and Cash Equivalents at Beginning of Year 18,650 20,372 -------- -------- Cash and Cash Equivalents at End of Period $ 14,480 $ 17,589 ======== ========
3 5 DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) NOTE 1--BASIS OF PRESENTATION The information for the three months ended March 31, 1999 and 1998 has not been audited by independent accountants, but includes all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for such periods. Certain information and footnote disclosure normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to the requirements of the Securities and Exchange Commission, although the Company believes that the disclosures included in these financial statements are adequate to make the information not misleading. The consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's 1998 annual report on Form 10-K as filed with the Securities and Exchange Commission. The results of operations for the three-month period ending March 31, 1999 are not necessarily indicative of the results to be expected for the year ended December 31, 1999. Basic earnings per share is computed by dividing net income by the weighted-average number of shares outstanding. Diluted earnings per share includes the dilutive effect of stock options. NOTE 2--INVENTORIES Inventories by major categories are summarized as follows:
(Dollars in Thousands) March 31, December 31, 1999 1998 -------- -------- Raw materials $ 19,262 $ 19,235 Work in process 19,587 19,317 Finished goods 15,469 15,526 -------- -------- Total $ 54,318 $ 54,078 ======== ========
NOTE 3--COMPREHENSIVE INCOME Comprehensive income is summarized as follows:
(Dollars in Thousands) Three Months Ended March 31, ----------------------- 1999 1998 -------- -------- Net income $ 4,100 $ 4,104 Foreign currency translation adjustment (6,425) (417) -------- -------- Comprehensive income (loss) ($ 2,325) $ 3,687 ======== ========
The Company does not provide for U.S. income taxes on foreign currency translation adjustments because it does not provide for such taxes on undistributed earnings of foreign subsidiaries. 4 6 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 4--SEGMENT AND PRODUCT LINE INFORMATION The Company considers its manufactured instruments and medical immunodiagnostic test kits as one operating segment as defined under SFAS 131, "Disclosures about Segments of an Enterprise and Related Information" as the kits are required to run the instruments and utilize similar technology and instrument manufacturing processes. The Company manufacturers its instruments and kits principally from facilities in the United States and the United Kingdom. Kits and instruments are sold to hospitals, medical centers, clinics, physicians, and other clinical laboratories throughout the world through a network of distributors including consolidated distributors located in the United Kingdom, Germany, Czech Republic, Poland, Spain, The Netherlands, Belgium, Luxembourg, Finland, Norway, France, Australia, New Zealand, China, Brazil, Uruguay, Venezuela, Costa Rica, Honduras, El Salvador, Guatemala, Panama, Sweden and Estonia. The Company sells its instruments and immunodiagnostic test kits under several product lines. Product line sales information is as follows:
(Dollars in Thousands) Three Months Ended March 31, --------------------------- 1999 1998 ------- ------- Sales: IMMULITE $33,197 $27,340 Radioimmunoassay ("RIA") 9,973 10,872 Other 7,296 7,892 ------- ------- $50,466 $46,104 ======= =======
The Company is organized and managed by geographic area. Transactions between geographic segments are accounted for as normal sales for internal reporting and management purposes with all intercompany amounts eliminated in consolidation. Sales are attributed to geographic area based on the location from which the instrument or kit is shipped to the customer. Information reviewed by the Company's chief operating decision maker on significant geographic segments, as defined under SFAS 131, is prepared on the same basis as the consolidated financial statements and is as follows:
(Dollars in Thousands) Euro/DPC DPC Limited Bierman DPC Medlab Less: United (United (German (Brazilian Intersegment States Kingdom) Group) Group) Other Elimination Total ------- --------- ------- ---------- ------- ------------ ------- Three Months Ended March 31, 1999 Sales $32,342 $ 7,191 $ 8,569 $ 5,031 $11,330 $(13,997) $50,466 Net income (loss) 1,957 1,130 (32) 2 443 600 4,100 Three Months Ended March 31, 1998 Sales $29,720 $ 6,332 $ 8,715 $ 4,822 $ 8,947 $(12,432) $46,104 Net income (loss) 3,251 892 (90) 43 108 (100) 4,104
5 7 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS RESULTS OF OPERATIONS The Company's sales increased 9.5% in the first quarter of 1999 to $50.5 million compared to sales of $46.1 million in the first quarter of 1998. Sales of all IMMULITE products (instruments and reagents) in the first quarter of 1999 were $33.2 million, a 22% increase over the first quarter of 1998. Sales of IMMULITE products represented 66% of first quarter 1999 sales, compared to 59% of first quarter 1998 sales. IMMULITE reagents represented $25.5 million of 1999 first quarter sales, a 24% increase. Sales of IMMULITE systems (including service revenue) were $7.7 million, up 15% over the first quarter of 1998. The Company shipped a total of 181 IMMULITE systems during the 1999 first quarter, including 78 IMMULITE 2000 systems and 103 IMMULITE One systems. The total base of IMMULITE systems shipped grew to approximately 4,150, including 368 of the IMMULITE 2000 systems. The Company's goal is to ship 400 IMMULITE 2000 systems in 1999. Because the IMMULITE 2000 system first became commercially available in April 1998, shipments of this product did not make a meaningful contribution to first quarter 1998 results. Sales of the Company's mature RIA products declined approximately 8% in the first quarter of 1999, representing 20% of sales, compared to 24% of sales in the first quarter of 1998. This trend is expected to continue. Sales of other DPC products, including allergy reagents, accounted for approximately 9% of 1999 first quarter sales and were essentially unchanged from the 1998 first quarter due to a soft allergy season in Asia. Sales of non-DPC products through its consolidated international affiliates decreased 11% in the first quarter of 1999 to $2.7 million (5% of sales). The devaluation of the Brazilian currency in January 1999 resulted in a $536,000 pretax exchange loss or after tax, $.03 per share. The expense is included in general and administrative expenses. In addition, the Company recorded a currency translation adjustment of $4.2 million resulting from the Company's long-term intercompany advances to Brazil. In accordance with the provisions of the Statement of Financial Accounting Standards No. 52, gains and losses arising from intercompany foreign currency transactions that are of a long-term investment nature (i.e. transactions for which settlement is not planned or anticipated in the foreseeable future) are accumulated in a separate component of shareholders' equity. The Brazilian devaluation also impacted ongoing operations in Brazil, where the Company is the market leader. When measured in the local currency, sales in the first quarter of 1999 were 8.9 million Brazilian Real compared to 5.4 million Real in the first quarter of 1998. When measured in U.S. dollars, sales were $5.0 million in the first quarter of 1999 (9.9% of total sales) compared to $4.8 million (10.4% of total sales) in the first quarter of 1998. Although the devaluation has slowed the Company's rapid sales expansion in that country, the Company believes that the situation is stabilizing. Due to the significance of foreign sales (79% of total sales), in particular in Europe, the Company is subject to currency risks based on the relative strength or weakness of the U.S. dollar. In periods when the U.S. dollar is strengthening the effect of the translation of the financial statements of consolidated foreign affiliates is that of lower sales and net income. Other than the effects of the currency devaluation in Brazil discussed above, currency translation effects did not have a material impact on 1999 first quarter results. In the first quarter of 1998, however, the strong U.S. dollar had a 7% negative impact on sales. Due to intense competition, the Company's foreign distributors are generally unable to increase prices to offset the negative effect when the U.S. dollar is strong. In the first quarter of 1999 domestic sales grew at a faster pace than foreign sales, 14% growth for domestic sales compared to 8.3% growth for foreign sales. Costs of sales as a percentage of sales increased from 44% in the first quarter 1998 to 46% in the first quarter 1999. Selling expense as a percentage of sales decreased slightly from 19.5% in the first quarter of 1998 to 18.9% in the first quarter of 1999, reflecting the end of pre-launch expenses for the IMMULITE 2000. 6 8 General and administrative expenses increased 14% in the first quarter of 1999 compared to the 1998 first quarter, and increased as a percentage of sales from 12.9% in 1998 to 13.4% in 1999 principally due to the $536,000 exchange loss from the Brazilian devaluation discussed above. Included in general and administrative expenses is the amortization of the excess of cost over net assets acquired and minority interest. Equity in income of affiliates represents the Company's share of earnings of non-consolidated affiliates, principally the 45%-owned Italian distributor. This amount increased almost 40% in the first quarter of 1999 compared to the first quarter of 1998 primarily due to increased earnings by the Italian and Portuguese distributors. Net interest income represents the excess of interest income and interest on equipment contracts over interest expense. Net interest income increased in the 1999 first quarter compared to the 1998 first quarter due to decreased borrowings during the period. The Company's effective tax rate includes Federal, state and foreign taxes. Lower than anticipated research and development tax credits increased the effective tax rate from 29.5% in the first quarter 1998 to 30.4% in 1999. Net income was $4.1 million ($.30 per share) in each of the first quarter of 1999 and 1998, but decreased as a percentage of sales from 8.9% in 1998 to 8.1% in 1999 due to the higher cost of sales and the effects of the Brazilian devaluation. LIQUIDITY The Company has adequate working capital and sources of capital to carry on its current business and to meet its existing capital requirements. Net cash flow from operating activities was $6.7 million in the first quarter of 1999 and $4.7 million in the first quarter of 1998. Additions to property, plant and equipment in the first quarter of 1999 were $2.9 million compared to $2.6 million in the first quarter of 1998. Cash flow used for the placement of IMMULITE systems under sales-type and operating leases (for periods of generally three to five years) was $4.5 million in the first quarter of 1999 compared to $2.1 million in the first quarter of 1998. The Company used cash to reduce borrowings by $1.2 million in the 1999 first quarter compared to $0.54 million cash provided by borrowings in the 1998 first quarter. The Company's foreign operations, particularly, at this time, its operations in Brazil, are subject to risks, such as currency devaluations, associated with political and economic instability. See discussion above under "Results of Operations" regarding the effects of the Brazilian devaluation. The Company expects to purchase real property in New Jersey in 1999 at a cost of approximately $2.8 million. The Company plans to construct an 80,000 square foot manufacturing facility on this property over the next several years at a cost between $8 million and $10 million. The Company has no other material commitments for capital expenditures in 1999. The Company has a $20 million unsecured line of credit under which there were no borrowings outstanding at March 31, 1999 and December 31, 1998. Standby letters of credit under the line of credit were zero at March 31, 1999 and $2 million at December 31, 1998. The Company had notes payable (consisting of bank borrowings by the Company's foreign consolidated subsidiaries payable in the local currency which are guaranteed by the Company) of $18.4 million at March 31, 1999 compared to $21.2 million at December 31, 1998. The Company has paid a quarterly cash dividend of $.12 per share since 1995. On October 14, 1998 the Company announced a plan under which it could repurchase up to one million shares of its common stock from time to time in open market transactions. Through March 31, 1999 the Company had repurchased a total of 208,288 shares at a cost of $4.3 million. The Company utilized existing cash to finance such purchases. Additional repurchases, if any, will depend on the prevailing market price of the Common Stock and could require bank borrowings. 7 9 EURO CONVERSION The Company has significant sales to European countries (the "participating countries") which began converting to a common legal currency (the "euro") on January 1, 1999. During the transition period of January 1, 1999 to January 1, 2002, public and private parties may pay for goods and services using either the euro or the local currency. During the transition period, conversion rates will not be computed directly from one local currency to another. Instead, local currencies will be converted first to a euro denomination and then to the second local currency. Beginning January 2002, new euro-denominated bills and coins become legal currency and all former currencies will, over the ensuing months, be withdrawn from circulation. The ultimate conversion to the euro will eliminate currency exchange risk among the participating countries. The Company sells its products in the participating countries through affiliated and non-affiliated distributors which determine sales prices in their respective territories. The use of a single currency in the participating countries may affect this variable pricing in the various European markets because of price transparency. Nevertheless, other market factors such as local taxes, customer preferences and product assortment may reduce the need for price equalization. The Company has significant sales in Europe and is currently evaluating the business implications of the conversion to the euro, including the need to adapt internal systems to accommodate euro-denominated transactions, the competitive implications of cross border price transparency, the impact on existing marketing programs, and other strategic implications. Due to the existence of many unknown variables at this early stage, it is not at this time possible for the Company to predict the precise implications of the euro conversion on its operations. YEAR 2000 The Company has a program to address Year 2000 readiness of its information and business systems. This program is more than half-way completed. The Company has tested all critical systems and has performed routine testing of work stations. Work stations that require corrective software have been identified and the Company's goal, subject to timely software manufacturer support, is to complete the remediation efforts by July 1999. The costs incurred to date and expected to be incurred in the future related to the evaluation and remediation efforts are not material. Independent of the Year 2000 issue, over the last 18 months the Company has been engaged in an ongoing program to upgrade its information systems. The Company has instituted a comprehensive vendor/supplier compliance verification program to assure that the Company will have an uninterrupted supply of goods, services and materials. The Company has requested compliance verification from all vendors/suppliers. The Company presently believes that, with modifications to existing software, the Year 2000 issue will not pose significant operational problems for the Company or its affiliates. However, if such modifications are not completed timely by the Company or any of its affiliates, or by significant third parties with whom the Company does business, such as communications and power providers, the Year 2000 issue could have a material impact on the operations of the Company. The Company maintains business continuity plans in all major sites to deal with potential business interruptions that could occur as a result of power or communications failures. The Company also has a program to determine whether its instrumentation products are Year 2000 compliant. The Company's website contains a regularly updated product compliance status page which customers can access to obtain information regarding the compliance status of their DPC products. The Company is also providing customer support and customer satisfaction services to all of its customers regarding 8 10 Year 2000 issues. The IMMULITE 2000 instrument, which the Company began shipping in March 1998, is Year 2000 compliant. The Company has determined that the IMMULITE One instrument is not Year 2000 compliant and has so informed the FDA. The software used in the IMMULITE One has a two-digit year field which must be changed to a four-digit field. As part of its routine, on-going software development, the Company is developing software for the IMMULITE One that will be Year 2000 compliant. The Company's goal is to be able to offer to its customers software and hardware upgrades to make all its products compliant by June 30, 1999. A relatively few older products are not compliant and will not be upgraded due to obsolescence. The costs incurred to date and expected to be incurred to upgrade products are not material. While the Company currently expects that it will be able to bring its own systems and products into Year 2000 compliance on a timely basis, if the Company encounters unforeseen problems or delays it could be subject to legal claims (with or without merit), increased warranty costs, or customer dissatisfaction which could result in a material adverse effect on the Company's business, financial condition and results of operations. FORWARD LOOKING STATEMENTS Except for the historical information contained herein, this report contains forward looking statements (identified by the words "estimate," "project," "anticipate," "expect," "intend," "believe," "hope" and similar expressions) which are based upon Management's current expectations and speak only as of the date made. These forward looking statements are subject to risks, uncertainties and factors that could cause actual results to differ materially from the results anticipated in the forward looking statements. These risks and uncertainties include the degree of customer demand for the Company's products, customer acceptance of the IMMULITE 2000 and other new products, the Company's ability to keep abreast of technological innovations, the risks inherent in the development and release of new products (such as delays, unforeseen costs and technical difficulties), competitive pressures, currency risks based on the relative strength or weakness of the U.S. dollar, health care regulation and cost containment measures, and political and economic instability in certain foreign markets. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK There has been no material change during the quarter ended March 31, 1999, from the disclosures about market risk provided in the Company's Annual Report on Form 10-K for the year ended December 31, 1998. 9 11 PART II. OTHER INFORMATION ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K. (a) Exhibits 27 Financial Data Schedule (b) Reports on Form 8-K. None. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DIAGNOSTIC PRODUCTS CORPORATION (Registrant) APRIL 29, 1999 /s/ SIGI ZIERING - --------------------------------- ---------------------------------------- Date Sigi Ziering, Ph.D., Chairman of the Board Chief Executive Officer APRIL 29, 1999 /s/ JULIAN R. BOCKSERMAN - --------------------------------- ---------------------------------------- Date Julian R. Bockserman, Vice President Chief Financial Officer 10 EX-27 2 FINANCIAL DATA SCHEDULE
5 1,000 3-MOS DEC-31-1999 JAN-01-1999 MAR-31-1999 14,480 0 53,852 130 54,318 126,239 104,729 50,946 241,420 44,918 0 0 0 37,826 158,676 241,420 50,466 50,466 23,206 23,206 21,370 0 0 5,890 1,790 4,100 0 0 0 4,100 .30 .30
-----END PRIVACY-ENHANCED MESSAGE-----